R. W. Dal Negro (Verona, Italy), B. Brashier (Pune, Maharashtra, India)
Reactive oxygen species concentrations are decreased by nebulized apocynin in exhaled breath condensate of healthy subjects
J. Stefanska, M. Sokolowska, D. Nowak, R. Pawliczak (Lodz, Poland)
|   |
Association of β2-adrenoreceptor genotype with bronchodilator responses (bdr) in COPD
H. Makita, S. Konno, M. Hasegawa, K. Shimizu, Y. Nasuhara, T. Betsuyaku, M. Nishimura, Hokkaido COPD Cohort Study Group (Sapporo, Japan)
| |
Treatment with inhaled corticosteroids (ICS) in patients with COPD: possible way of optimisation
K. Gashynova (Dnipropetrovsk, Ukraine)
| |
Long-term safety of inhaled formoterol in patients with COPD
P. Rytilä, M. Härkönen, R. Vaheri, P. Happonen (Espoo, Kuopio, Finland)
| |
Safety and feasibility of tight glycaemic control for COPD patients with exacerbations on the acute medical unit. Results of a phase IIa clinical trial
J. R. H. Archer, S. Misra, M. Simmgen, P. W. Jones, E. H. Baker (London, United Kingdom)
| |
Survey of dyspnoea in COPD patients on medication and preemptive use of a short-acting β-2 agonist
T. Saito, K. Shimizu, M. Matsuyama, N. Kokuho, Y. Miura, S. Otsuka, T. Kiwamoto, K. Hayashihara (Tokai-mura, Japan)
| |
Development of a primary outcome measure for a randomised controlled trial of tight glycaemic control for COPD exacerbations
E. H. Baker, K. Arshad, M. Khatib, P. W. Jones (London, United Kingdom)
| |
Tiotropium bromide exerts anti-inflammatory activity in a cigarette smoke mouse model of COPD
L. Wollin, M. Pieper (Biberach, Germany)
| |
Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms & morning activities in COPD patients
T. Welte, M. Miravitlles, P. Hernandez, L. Hartman, T. Polanowski, R. Kessler (Hannover, Germany; Barcelona, Spain; Halifax, Canada; Lund, Sweden; Strasbourg, France)
| |
Efficacy of erdosteine (E) in the treatment of exacerbated and stable chronic bronchitis or chronic obstructive pulmonary disease (CB/COPD): a meta-analysis of individual patient data
M. Cazzola, I. Floriani, C. P. Page (Roma, Milano, Italy; London, United Kingdom)
| |
Efficacy of lasolvan in the treatment of patients with chronic obstructive pulmonary disease
U. Farkhutdinov, S. Farkhutdinov, V. Petryakov (Ufa, Russian Federation)
| |
Less than 20% of COPD patients persist with long-acting inhaled drugs for at least three years
R. Gale, F. Penning-van Beest, M. van Herk-Sukel, J. W. Lammers, R. Herings (Rotterdam, Utrecht, Netherlands; West Sessex, United Kingdom)
| |
Influence of statin therapy on exacerbation frequency in patients with COPD
S. O. Tandogdu, E. Eryuksel, S. Karakurt, H. Senol, T. Celikel (Istanbul, Turkey)
| |
Persistency of antioxidant/antiinflammatory effects of erdosteine treatment in COPD
R. Dal Negro, C. Micheletto, S. Tognella, M. Visconti (Bussolengo (VR), Italy)
| |
Predicting response to corticosteroid in COPD using exhaled nitric oxide
J. Dummer, M. Epton, J. Cowan, J. Cook, R. Condliffe, E. Landhuis, A. Smith, R. Taylor (Dunedin, New Zealand)
| |
Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation-related antibiotic use in patients with COPD
T. Welte, M. Miravitlles, P. Hernandez, S. Peterson, T. Polanowski, R. Kessler (Hannover, Germany; Barcelona, Spain; Halifax, Canada; Lund, Sweden; Strasbourg, France)
| |
A nationwide questionnaire survey on clinical application of aerosol nebulization inhalation in China
J. P. Zheng, Y. L. Su, Y. Gao, J. Y. An, W. T. Liu, X. X. Yu (Guangzhou, China)
| |
Mucociliary clearance (MCC) disorders in patient with acute bronchitis (AB) and acute exacerbation (AE) of COPD and ways of it correction
T. Pertseva, K. Gashynova, O. Gurzhiy, N. Klimenko (Dnipropetrovs‘k, Ukraine)
| |
Dose response for inhaled fluticasone on airway and systemic inflammation in COPD
P. Williamson, D. Menzies, K. Clearie, S. Vaidyanathan, B. Lipworth (Dundee, United Kingdom)
| |
Four weeks of treatment with n-acetyl cysteine (NAC) (1200mg/day) reduces lung oxidative stress and improves lung function in moderate-to-severe COPD subjects
B. Brashier, L. Ravindaran, S. Kapoor, P. K. Deshpande, B. Ghongane, S. Madas, S. Mandrekar, S. Limaye, S. Salvi (Pune, India)
| |